Bupivacaine hydrochloride is named as an intervention in 12 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Beijing Tiantan Hospital (6). The most-studied condition is Liposomal Bupivacaine.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial
NCT06569953 · ClinicalTrials.gov ↗ · Acute Pain, Chronic Pain, Postoperative Pain
|
Phase 4 | Recruiting | The Second Affiliated Hospital of Chongqing Medical University | China |
|
Effect of Intercostal Nerve Block With Liposomal Bupivacaine on Quality of Recovery in VATS Partial Pneumonectomy
NCT07512635 · ClinicalTrials.gov ↗ · Pulmonary Nodule, Liposomal Bupivacaine
|
Phase 4 | Recruiting | Sanming First Hospital | China |
|
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
NCT06529432 · ClinicalTrials.gov ↗ · Local Analgesia Via Nerve Block
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery
NCT06704698 · ClinicalTrials.gov ↗ · Pain Syndrome, Dizziness, Vomiting
|
Not applicable | Recruiting | Zhejiang Cancer Hospital | China |
|
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
NCT07432711 · Video-assisted Thoracoscopic Surgery (VATS), Pain Management, Liposomal Bupivacaine
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
The Efficacy and Safety of Liposomal Bupivacaine for Rhomboid Intercostal Nerve Block in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery
NCT07441902 · ClinicalTrials.gov ↗ · Video-assisted Thoracoscopic Surgery (VATS), Pain Management, Liposomal Bupivacaine
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery
NCT07442539 · ClinicalTrials.gov ↗ · Hemorrhoid Surgery, Liposome Bupivacaine, Pain Management
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Laparoscopic Surgery
NCT07458256 · ClinicalTrials.gov ↗ · Laparoscopic Surgery, Liposomal Bupivacaine, Local Infiltration
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery
NCT07458282 · ClinicalTrials.gov ↗ · Laparoscopic Surgery, Liposomal Bupivacaine, Transversus Abdominis Plane Block
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology
NCT07458295 · ClinicalTrials.gov ↗ · Laparoscopic Surgery, Gynecologic Oncology Patient, Liposomal Bupivacaine
|
Not applicable | Recruiting | Beijing Tiantan Hospital | China |
|
The Effect of Liposomal Bupivacaine Erector Spinae Plane Block
NCT07667439 · ClinicalTrials.gov ↗ · Liposome Bupivacaine, Erector Spinae Plane Block, Postoperative Analgesia
|
Not applicable | Not yet open | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Effect of Liposomal Bupivacaine and Bupivacaine Hydrochloride for Superior Trunk Block of the Interscalene Brachial Plexus on Postoperative Diaphragmatic Function and Analgesia
NCT07587203 · ClinicalTrials.gov ↗ · Proximal Humerus Surgery, Rotator Cuff Surgery, Shoulder Arthroplasty
|
Not applicable | By invitation | Nanjing First Hospital, Nanjing Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
7 single-substance products containing Bupivacaine hydrochloride on the HPRA medicines list.
| Condition (as registered) | Trials |
|---|---|
| Liposomal Bupivacaine | 6 |
| Pain Management | 3 |
| Laparoscopic Surgery | 3 |
| Video-assisted Thoracoscopic Surgery (VATS) | 2 |
| Liposome Bupivacaine | 2 |
| Local Infiltration | 2 |
| Transversus Abdominis Plane Block | 2 |
| Local Injection | 1 |
| Acute Pain | 1 |
| Chronic Pain | 1 |
| Postoperative Pain | 1 |
| Pulmonary Nodule | 1 |
| Pain Syndrome | 1 |
| Dizziness | 1 |
| Vomiting | 1 |
| Itching | 1 |
| Local Analgesia Via Nerve Block | 1 |
| Hemorrhoid Surgery | 1 |
| Proximal Humerus Surgery | 1 |
| Rotator Cuff Surgery | 1 |
| Shoulder Arthroplasty | 1 |
| Shoulder Arthroscopy | 1 |
| Erector Spinae Plane Block | 1 |
| Postoperative Analgesia | 1 |
| Randomized Controlled Trial | 1 |
| Rhomboid Intercostal Block | 1 |
| Gynecologic Oncology Patient | 1 |
| Lead sponsor | Trials |
|---|---|
| Beijing Tiantan Hospital | 6 |
| The Second Affiliated Hospital of Chongqing Medical University | 1 |
| Sanming First Hospital | 1 |
| Zhejiang Cancer Hospital | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 12 | 10 |
A trial with sites in more than one country appears in each of those registers.
12 current trials in our China register name Bupivacaine hydrochloride as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 10 of the 12 trials are recruiting: 10 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Beijing Tiantan Hospital (6), The Second Affiliated Hospital of Chongqing Medical University (1), Sanming First Hospital (1) and Zhejiang Cancer Hospital (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 7 single-substance products containing Bupivacaine hydrochloride, for example Bupivacaine Heavy 5 mg/ml solution for injection (Laboratoire Aguettant). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 2 entries for Bupivacaine hydrochloride: US FDA: current; US FDA: current. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bupivacaine hydrochloride works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bupivacaine hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bupivacaine hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.